On April 25-26, Yin Ye, CEO of BGI Genomics, and his delegation visited Serbia and signed a memorandum of understanding with the Serbian Ministry of Health on cooperation in public health and precision testing.

Werfen on Thursday announced a partnership agreement with Thermo Fisher Scientific for worldwide distribution of the TCAutomation laboratory automation system as part of the HemoCell Specialized Lab Automation system for hemostasis diagnostic testing.

Stockholm, Sweden-based Devyser Diagnostics on Monday announced that it has inked a collaboration and distribution agreement that gives Thermo Fisher Scientific the exclusive rights to commercialize its post-transplant portfolio of next-generation sequencing (NGS) products in North America and Europe.

On April 18, Sino Biological Inc., a protein and antibody R&D and production expert, signed a strategic cooperation agreement with Megarobo.

BioMérieux and JMI Laboratories announced that they have entered a six-year project to evaluate the performance of tests for antimicrobial resistance.

Juntendo University, Sysmex, and ThinkCyte said Tuesday that they are collaborating on research into the early detection and treatment of chronic myelogenous leukemia (CML).

Molecular pathology firm Xyall and digital pathology firm Indica Labs said Monday that they have inked a global partnership to combine their technologies to deliver a fully digital and automated workflow for tissue macro dissection for molecular diagnostic testing.

Oxford Nanopore Technologies plc and bioMérieux SA announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Agena Bioscience and nRichDX said Friday that they have entered a commercial partnership to co-promote their products to researchers developing liquid biopsy applications on Agena's MassArray platform.

Naveris said Wednesday that Mayo Clinic began a Phase II trial of its circulating tumor DNA blood test, NavDx, to guide treatment for patients with HPV-driven head and neck cancer.